Roche Launches Phase III Study of Rheumatoid Arthritis Drug for COVID-19 Pneumonia


Every human life is precious and sacred, saving one is like saving the whole of humanity. (Al Quran 5:32/33)

Source: Biospace

By Alex Keown

Days after Swiss pharma giant Roche began shipping hundreds of thousands of its recently-approved COVID-19 test to laboratories in the United States, the company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.

This morning, Roche said it was launching a Phase III trial of Actemra (tocilizumab) plus standard-of-care in hospitalized patients with this type of pneumonia. Following treatment, patients in the trial will be followed for 60 days post-randomization, and an interim analysis will be conducted to look for early evidence of efficacy, Roche said. This is the first global study of Actemra in this setting and the company said it anticipates enrolling patients beginning in April. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables, Roche said.

Actemra is an IL-6 inhibitor. The IL-6 protein triggers the body’s immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, inhibiting IL-6 could keep the body from attacking itself. As COVID-19 continues to spread across the globe, there have been reports that some physicians in China have been using Actemra in a number of patients who are showing overactive immune responses to the novel coronavirus. The immune systems of these patients have been attacking healthy tissues and organs, including their lungs. The Chinese physicians prescribed Actemra in order to calm those immune responses. Last week, Regeneron and Sanofi announced they would be testing their IL-6 inhibitor Kevzara as a potential treatment following these reports. Citing reports from that country, Regeneron Chief Scientific Officer George Yancopoulos told reporters that patients who received the Roche treatment “got out of death’s bed and walked out of the hospital.” Actemra has now been included in diagnosis and treatment plan for COVID-19 issued by China’s National Health Commission.

Read further


Dr. Zia H Shah, Chief Editor of the Muslim Times and in charge of health section

Suggested reading by Zia H Shah MD, Chief Editor of the Muslim Times

Corona Fear’s Cure: Chanting from the Bible and the Quran

The self isolation for 70 years and older may last up to 4 months

Does the Ordinary Soap Kill Coronavirus?

Most Dramatic Quarantine: Northern Italy quarantines 16 million people

Islam: China has made eating wild animals illegal after the coronavirus outbreak?

All of humanity are intimate neighbors: Coronavirus proves it once again

Here’s a list of disinfectants you can use against coronavirus

To see the daily new cases and deaths in the top eleven countries go to

Coronavirus: UK expected to move to ‘delay’ phase

When Not Going to Jumma is a Huge Blessing

“We project that roughly 56 percent of our population – 25.5 million people – will be infected with the virus over an eight week period,” Governor Newsom of California wrote on 3/19/2020.

Categories: Health, The Muslim Times

Leave a Reply